IGF-1 DES

IGF-1 DES is a 67-amino-acid truncated analog of native human insulin-like growth factor 1 (IGF-1), missing the first three N-terminal amino acids (Gly-Pro-Glu, the GPE tripeptide). The compound was originally identified as a naturally occurring IGF-1 variant in bovine colostrum (Francis 1988) and later in human placenta and other tissues. The N-terminal truncation dramatically alters two properties simultaneously: binding affinity for IGF-binding proteins (IGFBPs) is reduced, freeing more peptide for receptor engagement, while binding affinity at the IGF-1 receptor (IGF1R) is increased by approximately 5-10 times compared to native IGF-1. The compound activates the same downstream signaling cascade as native IGF-1 (PI3K-AKT-mTOR for protein synthesis, MAPK for cell proliferation) but with much higher potency per molecule. The plasma half-life is very short (10-20 minutes), making IGF-1 DES suitable for site-specific local action rather than systemic exposure. The compound has never undergone human clinical trials, has no FDA approval, and is on the FDA Category 2 bulks list. IGF-1 DES is used off-label in bodybuilding for site-specific muscle targeting and is WADA-prohibited under Section S2.

Discovery and Biology of IGF-1 DES

IGF-1 DES was originally identified by Francis and colleagues at the University of Adelaide as a naturally occurring IGF-1 variant in bovine colostrum. The Francis 1988 Biochemical Journal paper documented the structure and demonstrated that the truncated form retained biological activity. Subsequent work, notably the Bagley 1989 paper, characterized the functional role of the N-terminal residues and demonstrated the dramatic effect of removing the first three amino acids on IGF1R affinity and IGFBP binding.

The N-terminal pentapeptide of IGF-1 (Gly-Pro-Glu-Thr-Leu) sits in a region that engages both the IGF-1 receptor and the IGF-binding proteins. The first three residues (Gly-Pro-Glu, the GPE tripeptide) are particularly important for IGFBP binding. Removal of these three residues produces 5-10x increased binding affinity at IGF-1 receptor, dramatically reduced binding to IGFBPs, higher free fraction of administered peptide, higher per-molecule potency, and a short plasma half-life of 10-20 minutes.

The combination of high receptor affinity and short half-life is the practical signature of IGF-1 DES: very potent local action with minimal sustained systemic exposure.

The N-Terminal GPE Tripeptide

The removed N-terminal tripeptide (Gly-Pro-Glu, GPE) is itself a bioactive peptide. Free GPE has been studied for its own pharmacological effects, particularly in neurology (where it has been investigated for neuroprotective effects in stroke and traumatic brain injury models). Some published work refers to GPE as Glypromate.

Comparison with Other IGF-1 Variants

The three principal IGF-1 variants used in research and off-label contexts have distinct profiles:

Native IGF-1 (mecasermin, Increlex): 70 amino acids, full sequence identical to endogenous IGF-1. FDA-approved for severe primary IGF-1 deficiency in pediatric patients. Half-life 12-15 minutes (unbound). High IGFBP-3 binding. Standard reference compound for IGF-1 pharmacology.

IGF-1 LR3 (Long R3 IGF-1): 83 amino acids: 70-aa IGF-1 + N-terminal 13-aa extension + Arg3 substitution. No FDA approval, on FDA Category 2 bulks list. Half-life 20-30 hours due to reduced IGFBP binding. Used for systemic, sustained exposure in off-label bodybuilding. WADA-prohibited under S2.

IGF-1 DES: 67 amino acids, native IGF-1 minus the N-terminal Gly-Pro-Glu tripeptide. No FDA approval, on FDA Category 2 bulks list. Half-life 10-20 minutes. 5-10x higher IGF1R affinity than native IGF-1. Reduced IGFBP binding. Used for site-specific local effects in off-label bodybuilding. WADA-prohibited under S2.

The three variants are not interchangeable. Selection depends on whether the goal is systemic exposure (LR3), site-specific local effect (DES), or pediatric clinical replacement therapy (mecasermin, only with specific indication).

Animal Studies on IGF-1 DES

Animal research on IGF-1 DES, primarily from the original Adelaide group and follow-up studies, documents anabolic potency in growth models (Tomas 1992 Biochemical Journal: IGF-1 DES anabolic effects in dexamethasone-treated rats with greater potency than native IGF-1), effects on muscle protein synthesis in juvenile animals, local muscle effects with site-specific intramuscular administration producing local hypertrophy in animal models, satellite cell activation, wound healing acceleration in some animal studies, and standard IGF-1 receptor activation profile across cell types.

Absence of Human Clinical Trials

A defining characteristic of IGF-1 DES is the complete absence of human clinical trials: no Phase 1, 2, or 3 clinical trials registered with FDA or EMA, no human pharmacokinetic studies of the DES variant specifically, no safety studies in human populations, and no efficacy studies for any indication. This is a significant evidence gap given the off-label use in bodybuilding contexts.

Off-Label Bodybuilding Use

The dominant current use of IGF-1 DES is off-label in bodybuilding contexts. Typical protocols: 20-50 mcg intramuscularly per site, pre- or post-workout. Site-specific injection into the muscle group being trained. Cycle length 4 weeks. Often combined with IGF-1 LR3 (for systemic effects) and PEG-MGF in stacks. Combined with anabolic-androgenic steroids in advanced bodybuilding contexts. Evidence quality is anecdotal, uncontrolled, almost always confounded by concurrent compound use.

Regulatory Status

• FDA: Not approved. Added to FDA Category 2 bulks list, prohibiting compounding pharmacy preparation
• EMA: Not approved
• WADA: Prohibited at all times in and out of competition under Section S2
• Research-chemical channels: principal access route. Quality variable

IGF-1 DES's mechanism is identical to native IGF-1 at the receptor level: full agonist activity at the IGF-1 receptor (IGF1R). The N-terminal truncation modifies pharmacokinetics, IGFBP binding, and receptor affinity without altering the fundamental molecular biology of receptor activation.

IGF-1 Receptor Activation

The IGF-1 receptor is a tyrosine kinase receptor structurally and functionally related to the insulin receptor. IGF-1 DES binding triggers receptor dimerization and autophosphorylation, recruitment and activation of insulin receptor substrate (IRS) proteins, PI3K-AKT-mTOR pathway activation for protein synthesis (mTORC1 phosphorylates 4E-BP1 and S6K1), RAS-MAPK pathway activation for cell proliferation, GLUT4 translocation and glucose uptake at higher concentrations, and inhibition of proteasomal protein degradation.

The principal anabolic effect in skeletal muscle is increased protein synthesis through mTORC1 activation combined with reduced proteolysis.

Effects of the N-Terminal Truncation

The removal of the N-terminal Gly-Pro-Glu tripeptide produces several simultaneous effects: increased IGF1R affinity (5-10x higher than native IGF-1 in standard binding assays), reduced IGFBP binding (the N-terminal region is part of the IGFBP binding interface), short half-life retained (unlike IGF-1 LR3 which extends half-life through N-terminal extension), and higher per-molecule potency (approximately 10-fold higher biological potency per molecule than native IGF-1).

Receptor Cross-Reactivity

At high concentrations, IGF-1 DES can cross-react with the insulin receptor (IR), producing insulin-like metabolic effects including hypoglycemia. This is the principal acute safety concern.

Local vs Systemic Action

The combination of high receptor affinity and short plasma half-life produces a distinctive pharmacological profile: intramuscular injection produces high local IGF1R activation at the injection site, the peptide is rapidly cleared from circulation limiting systemic exposure, this is the pharmacological basis for the site-specific local action used in bodybuilding contexts, and the theoretical advantage over IGF-1 LR3 for targeted muscle group effects. The practical limitation is that the local action rationale has not been rigorously validated in human studies.

Cancer and Mitogenic Signaling

IGF-1 receptor signaling is implicated in proliferation of many cancer types (Pollak 2008 Nature Reviews Cancer). Local IGF-1 DES administration could theoretically promote progression of any pre-existing or undiagnosed malignancy in the injected tissue area. The short half-life limits systemic mitogenic exposure but does not eliminate local concerns.

Effects in preclinical models (animal studies):

• Greater per-molecule anabolic potency than native IGF-1 in muscle growth models
• Site-specific muscle hypertrophy with localized injection
• Effects on satellite cell activation
• Wound healing acceleration in some models
• Growth effects in juvenile animals
• Cancer model effects: enhanced tumor growth in some animal models (mitogenic concerns)

Effects in clinical experience with mecasermin (native IGF-1) (indirect evidence relevant to IGF-1 DES safety profile):

• Hypoglycemia (dose-limiting)
• Lymphoid tissue hypertrophy
• Slipped capital femoral epiphysis (growth plate effect)
• Intracranial hypertension
• Scoliosis progression in predisposed patients
• Allergic reactions

Effects in off-label IGF-1 DES bodybuilding use (anecdotal, uncontrolled):

• Reported site-specific muscle growth at injection sites
• Reported enhanced local muscle pump
• Reported recovery enhancement
• Reported hypoglycemia at higher doses
• Highly variable individual response
• Heavy confounding from concurrent compound use

Effects in human clinical trials of IGF-1 DES specifically: none. No published human clinical trials of the DES variant exist.

Honest evidence framing: IGF-1 DES has clear biological rationale based on the well-characterized effects of N-terminal truncation on IGF1R affinity and IGFBP binding. Animal data supports the higher per-molecule potency profile. The pharmacokinetic profile (short half-life, high receptor affinity) is real and pharmacologically distinct from IGF-1 LR3. However, the absence of human clinical trials means safety and efficacy in humans rest on indirect inference from mecasermin clinical data, animal studies of the DES variant, and anecdotal bodybuilding reports. The cancer signaling concerns from IGF-1 receptor activation are real and pharmacologically expected. The site-specific local action rationale used in bodybuilding contexts, while pharmacologically plausible, has not been rigorously validated in human studies.

Important note: IGF-1 DES has no FDA-approved dosing protocol and no published human clinical dosing data. All doses described below come from bodybuilding-community practice.

Common off-label bodybuilding protocols:

• Standard site-specific protocol: 20-50 mcg intramuscularly per injection site, pre- or post-workout
• Multiple-site protocol: 5-20 mcg per site, several sites for distributed muscle group targeting
• Cycle length: typically 4 weeks
• Daily dosing on training days, often paired with workout timing

Routes: intramuscular is most common, injected directly into target muscle group. Subcutaneous is less common, less aligned with site-specific rationale. Pre-workout timing 15-30 minutes pre-training to coincide with workout-induced anabolic signaling. Post-workout timing immediately post-training during anabolic window.

Reconstitution and storage: lyophilized peptide reconstituted with bacteriostatic water or 0.9% sodium chloride. Acidic reconstitution may be needed for some preparations. Refrigeration after reconstitution (2-8°C). Stability typically 2-4 weeks at 2-8°C.

Stacking considerations: commonly stacked with IGF-1 LR3 for combined systemic and local effects. Combined with PEG-MGF for satellite cell activation plus protein synthesis. Combined with GHRPs and GHRH analogs. Combined with testosterone or anabolic steroids in advanced bodybuilding contexts. Combined with insulin in some protocols (significant hypoglycemia risk).

Comparison with mecasermin clinical dosing: mecasermin (Increlex) is dosed at 0.04-0.12 mg/kg twice daily SC for pediatric SPIGFD. IGF-1 DES off-label dosing is 20-50 mcg per injection (not weight-based, not clinical).

Special populations:

• Pregnancy: contraindicated. No safety data
• Breastfeeding: avoid
• Pediatric: contraindicated. Growth plate concerns
• Active or history of malignancy: contraindicated due to mitogenic concerns
• Diabetic retinopathy: relative contraindication
• Severe insulin sensitivity disorders: caution
• Athletes subject to WADA testing: prohibited at all times

Adverse effects observed in mecasermin (native IGF-1) FDA-approved use (provides indirect evidence for IGF-1 DES safety profile):

• Hypoglycemia: most common and dose-limiting. Particularly with fasting or inadequate caloric intake. Acute risk of severe hypoglycemia
• Lymphoid tissue hypertrophy: tonsils, adenoids, spleen
• Intracranial hypertension (pseudotumor cerebri): rare but serious
• Slipped capital femoral epiphysis: growth plate effect in growing children
• Scoliosis progression: in patients with pre-existing scoliosis
• Injection-site reactions: lipohypertrophy, lipoatrophy, pain
• Allergic reactions: rare but reported

Adverse effects reported in off-label IGF-1 DES bodybuilding use (anecdotal):

• Hypoglycemia (common acute issue, less severe than with IGF-1 LR3 due to shorter half-life)
• Local injection-site reactions
• Lipohypertrophy at repeatedly used injection sites
• Local muscle tissue effects (theoretical concerns about local fibrosis with chronic use)
• Headache
• Mild gut discomfort
• Sleepiness or fatigue
• Variable response

Theoretical and class-effect concerns:

• Cancer initiation and progression: chronic IGF-1 receptor activation is implicated in multiple cancer types. Local injection raises specific concerns about effects on pre-existing or undiagnosed local tumors. Practical risk from off-label use is unquantified but real
• Acromegaly-like effects: chronic high-dose IGF-1 axis activation can produce features overlapping with acromegaly
• Local fibrosis: theoretical concern with repeated injection at same site
• Cardiac effects: less likely than with sustained-exposure IGF-1 LR3, but not eliminated
• Insulin resistance: chronic exposure can promote insulin resistance
• Mitogenic effects on local tissues: kidney, spleen, liver, lymphoid tissues exposed to high local concentrations
• Research-chemical quality variability: significant practical concern. Identity, purity, endotoxin content, and proper folding vary substantially between suppliers

Contraindications and cautions: active malignancy or significant history of malignancy, diabetic retinopathy, pregnancy and breastfeeding, pediatric and adolescent use (open growth plates), hypersensitivity to the peptide, severe hypoglycemia history, athletes subject to anti-doping testing.

Drug interactions:

• Insulin: significant additive hypoglycemia risk. Stacking is dangerous
• Oral hypoglycemics: additive hypoglycemia risk
• Growth hormone and GHRPs: synergistic IGF-1 axis activation
• Corticosteroids: opposing effects on muscle protein synthesis
• Anabolic-androgenic steroids: additive anabolic effects through different mechanisms

IGF-1 DES sits within the IGF-1 family used in off-label bodybuilding contexts. Its closest comparators:

• Mecasermin (Increlex): FDA-approved recombinant native IGF-1. Pediatric severe primary IGF-1 deficiency indication. The only clinically validated IGF-1 product. Different practical profile (full sequence, normal IGFBP binding) than DES
• IGF-1 LR3: 83-aa synthetic analog with extended 20-30 hour half-life. Used systemically. Different practical profile (sustained exposure) than DES (site-specific local action)
• MGF (Mechano Growth Factor): IGF-1Ec splice variant with 24-aa C-terminal E-peptide. Different mechanism (satellite cell activation through non-IGF1R pathway). Half-life 5-7 minutes
• PEG-MGF: pegylated MGF with 24-72 hour half-life. Often stacked with IGF-1 DES for combined satellite cell activation and high-potency local protein synthesis

Common stacks circulating in bodybuilding contexts:

• IGF-1 DES + IGF-1 LR3: combined systemic (LR3) and local (DES) IGF-1 axis activation
• IGF-1 DES + PEG-MGF: combined satellite cell activation (PEG-MGF) and high-potency local protein synthesis (DES) at the injected muscle site
• IGF-1 DES + GH/GHRPs: combined GH elevation with site-specific IGF-1 axis activation
• IGF-1 DES + Testosterone/AAS: combined anabolic effects through different mechanisms
• IGF-1 DES + Insulin: dangerous combination with significant hypoglycemia risk

Combinations to avoid or use with caution: insulin (significant additive hypoglycemia risk), active malignancy (contraindicated, local injection raises specific concerns about local tumor effects), pregnancy and breastfeeding, pediatric and adolescent use (growth plate effects), diabetic retinopathy, WADA-tested athletes (prohibited under S2).

The most actionable framing of IGF-1 DES in 2026: this is a 67-amino-acid truncated IGF-1 analog with distinct pharmacological properties (5-10x higher IGF1R affinity, short half-life, reduced IGFBP binding) that produce a site-specific local action profile distinct from both native IGF-1 and IGF-1 LR3. The biological rationale is clear and pharmacologically sensible. The absence of human clinical trials means safety and efficacy rest on indirect inference from mecasermin clinical data and animal studies. The principal serious safety concerns are hypoglycemia (acute, dose-limiting), mitogenic effects on pre-existing or undiagnosed cancers, and acromegaly-like effects with chronic high-dose use. Research-chemical quality is variable. WADA prohibition is unambiguous. The site-specific local action used in bodybuilding contexts is pharmacologically plausible but has not been rigorously validated in humans. For users pursuing muscle hypertrophy without the DES risk profile, well-validated alternatives (progressive resistance training with adequate nutrition, and where medically appropriate, physician-supervised testosterone replacement) have substantially stronger evidence bases.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.